| 发明名称 |
Methods for treating HCV |
| 摘要 |
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. |
| 申请公布号 |
US9452194(B2) |
申请公布日期 |
2016.09.27 |
| 申请号 |
US201414503849 |
申请日期 |
2014.10.01 |
| 申请人 |
AbbVie Inc. |
发明人 |
Awni Walid M.;Bernstein Barry M.;Brun Scott C.;Cohen Daniel E.;Dumas Emily O.;Dutta Sandeep;Khatri Amit;Klein Cheri E.;Menon Rajeev M.;Mensing Sven;Podsadecki Thomas J. |
| 分类号 |
A01N43/04;A61K31/70;A61K38/07;A61K31/4025;A61K31/4178;A61K31/4709;A61K31/4725;A61K31/497;A61K31/513;A61K45/06;A61K31/427;A61K31/439;A61K31/7056;A61K31/7072;A61K31/5377;A61K38/06 |
主分类号 |
A01N43/04 |
| 代理机构 |
|
代理人 |
Zhang Xu |
| 主权项 |
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to a patient infected with HCV genotype 1, wherein said treatment lasts for 24 weeks and does not include administration of interferon to said patient, wherein said at least two DAAs comprise Compound 1and Compound 4and wherein Compound 1 is administered with ritonavir. |
| 地址 |
North Chicago IL US |
